Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank13
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P13
Within normal range
vs 5Y Ago
-3.5x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -61.80% |
| Q3 2025 | 38.79% |
| Q2 2025 | -4.92% |
| Q1 2025 | -15.28% |
| Q4 2024 | -20.66% |
| Q3 2024 | 20.60% |
| Q2 2024 | 23.36% |
| Q1 2024 | 2.09% |
| Q4 2023 | -29.50% |
| Q3 2023 | 91.53% |
| Q2 2023 | -21.33% |
| Q1 2023 | 61.87% |
| Q4 2022 | 4533.33% |
| Q3 2022 | -86.36% |
| Q2 2022 | -50.00% |
| Q1 2022 | 141.90% |
| Q4 2021 | -206.06% |
| Q3 2021 | 17.86% |
| Q2 2021 | -47.50% |
| Q1 2021 | -2.00% |
| Q4 2020 | 17.60% |
| Q3 2020 | -16.30% |
| Q2 2020 | 17.86% |
| Q1 2020 | -7.89% |
| Q4 2019 | 16.14% |
| Q3 2019 | 165.52% |
| Q2 2019 | -70.02% |
| Q1 2019 | 301.92% |
| Q4 2018 | 4.34% |
| Q3 2018 | 11.18% |
| Q2 2018 | 2.52% |
| Q1 2018 | 1028.99% |
| Q4 2017 | -106.50% |
| Q3 2017 | -27.17% |
| Q2 2017 | 421.81% |
| Q1 2017 | -72.65% |
| Q4 2016 | -17.64% |
| Q3 2016 | -11.99% |
| Q2 2016 | -17.62% |
| Q1 2016 | 158.88% |